The global immunohistochemistry market size was valued at USD 1.8 billion in 2019 and is expected to witness lucrative growth at a CAGR of 7.8% over the forecast period. Factors such as the introduction of technologically advanced immunohistochemistry solutions, increasing drug discovery and development activities, and rising prevalence of chronic diseases are expected to significantly fuel immunohistochemistry (IHC) market growth during the forecast period.
Immunohistochemistry, as a crucial application of monoclonal and polyclonal antibodies, helps understand tissue distribution of an antigen. It is used in the identification of enzymes, tumor suppressor genes, antigens, and tumor cell proliferation. IHC has gained popularity in the field of clinical diagnostics as it is used in the diagnosis of chronic diseases such as cancer, infectious diseases, cardiovascular diseases, and autoimmune disorders. Thus, the growing prevalence of chronic diseases is anticipated to increase the demand for immunohistochemistry solutions contributing to market growth.
Increasing product approvals and the introduction of technologically advanced immunohistochemistry solutions for disease diagnosis is further fueling the growth of the market for immunohistochemistry. For instance, in September 2019, U.S.-based Biocare Medical, LLC launched p16 INK4a, a novel mouse monoclonal antibody, intended for the qualitative detection of the p16 INK4a protein by IHC. In addition to this, in 2018, F. Hoffmann-La Roche AG, one of the prominent players in the IHC market introduced its new automated Ventana pan-tropomyosin receptor kinase (TRK) (EPR17341) Assay. This newly launched IHC assay is intended for the detection of TRK proteins in patients suffering from cancer.
Furthermore, major players involved in the development of IHC solutions are collaborating with the pharmaceutical drug manufacturers to develop and provide IHC companion diagnostic solutions for their immunotherapies. For instance, in May 2018, F. Hoffmann-La Roche AG collaborated with Five Prime Therapeutics, Inc. to provide IHC companion diagnostic assays for use with Five Prime’s, bemarituzumab, an investigational anti-FGFR2b antibody. Such strategic initiatives by key players are expected to create a lucrative environment for the growth of the market for immunohistochemistry.
Lack of specificity associated with IHC techniques and its high setup cost is anticipated to impede the growth of the market for immunohistochemistry. Accurate and early diagnosis of cancerous growth is very important in disease management. However, there is a lack of specificity with IHC techniques to diagnose some of the chronic diseases, which may hamper its adoption. The high setup cost of IHC equipment poses a huge burden on hospitals and diagnostic laboratories in developing economies, thereby limiting the growth of the market for immunohistochemistry.
On the basis of product, the market for immunohistochemistry is segmented into equipment, antibodies, reagents, and kits. In 2019, antibodies held the largest market share owing to their continuous usage in IHC procedures for disease diagnosis and drug testing. Therapeutic monoclonal antibodies and antibody-related products such as antibody fragments, Fc-fusion proteins, and antibody-drug conjugates have become the leading product class in the market. Antibodies are further segmented into primary and secondary antibodies. The primary antibodies segment dominated the market for immunohistochemistry in 2019 as these are primarily used in the diagnosis of chronic diseases and are anticipated to maintain their market share during the forecast period.
Kits used in IHC procedures consist of various products that are customized to suit the needs of clinicians. These include staining kits, antibody kits, reagent kits, and other reagents used in IHC. The kits segment is anticipated to witness the highest growth rate during the forecast period owing to their compact nature and convenience offered by them. IHC kits are commonly used in research laboratories and academic institutions that require these products in small quantities for conducting research, unlike other end use settings that require them in bulk quantities.
On the basis of application, the IHC market is segmented into drug testing and diagnostics. The diagnostics segment held the largest market share in 2019 and is expected to witness a lucrative CAGR during the forecast period. The diagnostics segment is further divided into cancer, diabetes, autoimmune, cardiovascular, infectious, and nephrological diseases. The global rise in the prevalence of these chronic diseases is boosting the demand for rapid and accurate diagnosis, thereby driving the growth of the diagnostics segment.
IHC technique is widely used in the field of drug discovery and testing. Thus, increasing R&D activities by pharmaceutical companies for the discovery and development of novel drugs is expected to raise demand for IHC solutions and support the segmental growth. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2018 PhRMA member biopharmaceutical research companies have invested around USD 79.6 billion for discovery and development of novel medicines.
Based on end-use, the market for immunohistochemistry is segmented into research institutes, hospitals and diagnostic laboratories, and others. Hospitals and diagnostic laboratories held the largest market share in 2019 owing to an increase in the demand for disease diagnosis due to the rise in the incidence of chronic diseases. Furthermore, technological advancements such as automated sample preparation and digital pathology have added considerable value. In addition, the rise in the number of hospitals and clinical research laboratories has also increased the demand for diagnostics, thus driving the growth of the segment.
Research institutes are estimated to exhibit a lucrative CAGR during the forecast period. Rising adoption of IHC solutions in research institutes for drug discovery and development activities has led to such high growth. The other end use segment includes contract research organizations (CROs) and forensic laboratories. The increasing trend toward the outsourcing of drug development activities by pharmaceutical and biotech companies is expected to support the growth of CROs segment.
In 2019, North America held a leading position in terms of revenue and is anticipated to hold its dominance in the IHC market over the forecast period. North America has a well-established healthcare infrastructure, which has led to an increase in the adoption of IHC instruments in laboratories and diagnostic centers. The supportive reimbursement framework in this region is also boosting the penetration of automated instruments in the market for immunohistochemistry. The incidence of cancer is also increasing in this region, which is further driving the demand for IHC techniques, thereby leading to lucrative market growth.
The Asia Pacific is expected to exhibit the highest growth owing to rapid economic development in countries such as China, India, South Korea, and Singapore. In addition, the rapidly aging population and the high prevalence of chronic diseases are also anticipated to be significant factors driving the market for immunohistochemistry. Based on WHO estimates, between 2010 and 2030 annual events of CVDs are predicted to rise by 50% in China.
Some of the key players operating in the market for immunohistochemistry comprise Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; Perkinelmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Agilent Technologies, Inc.; and Abcam plc.
Major players focus on adopting organic growth strategies such as product development and product upgradation in order to strengthen its market position and to capture a major market share. For instance, in March 2018, Germany-based Leica Biosystems, a wholly-owned subsidiary Danaher Corporation launched an upgraded version of its BOND-III IHC and ISH stainer. This newly launched innovative version of the BOND-III has enhanced the ease-of-use of both the instrument hardware and software. Similarly, in January 2017, PerkinElmer announced the launch of Vectra Polaris, Automated Quantitative Pathology Imaging System. This device is designed to provide researchers with an enhanced understanding of cancer immunotherapy approaches.
Base year for estimation
Actual estimates/Historical data
2016 - 2018
2020 - 2027
Revenue in USD Million & CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global immunohistochemistry market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Slide Staining Systems
Tissue Processing Systems
Blocking sera and Reagents
Application Outlook (Revenue, USD Million, 2016 - 2027)
End-use Outlook (Revenue, USD Million, 2016 - 2027)
Hospitals & Diagnostic Laboratories
Regional Outlook (Revenue, USD Million, 2016- 2027)
b. The global immunohistochemistry (IHC) market size was estimated at USD 1.7 billion in 2019 and is expected to reach USD 1.8 billion in 2020.
b. The global immunohistochemistry (IHC) market is expected to grow at a compound annual growth rate of 7.9% from 2020 to 2027 to reach USD 3.1 billion by 2027.
b. Antibodies dominated the immunohistochemistry (IHC) market with a share of 33.9% in 2019. This is attributable to to their continuous usage in IHC procedures for disease diagnosis and drug testing.
b. Some key players operating in the immunohistochemistry (IHC) market include Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc.
b. Key factors that are driving the market growth include introduction of technologically advanced immunohistochemistry solutions, increasing drug discovery and development activities, and rising prevalence of chronic diseases.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.